“Combination treatments of imatinib with astaxanthin and crocin efficiently ameliorate antioxidant status, inflammation and cell death progression in imatinib-resistant chronic myeloid leukemia cells”

Golestani, Amin; Rahimi, Atefeh; Najafzadeh, Mahsa; Sayadi, Mahtab; Sajjadi, Seyed Mehdi

doi:10.1007/s11033-023-09135-4

Cited by 3 publications

(1 citation statement)

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A myeloproliferative neoplasm stemming from myeloid CD34 + / CD38 − /CD90 + progenitors in the bone marrow (BM) causes chronic myelocytic leukemia (CML). As a result of the fusion of the Abelson murine leukemia (ABL) genome, chromosome 9, having the breakpoint cluster region (BCR) gene on chromosome 22, and the subsequent expression of an oncoprotein named BCR-ABL, the pathogenesis of CML occurs [ 179 – 181 ]. Several studies have demonstrated the potential of inducing ferroptosis for the treatment of chronic leukemia, especially for aggressive malignancies resistant to conventional therapies [ 177 , 182 – 184 ].…”

Section: Promoting Ferroptosis As a Novel Leukemia Treatment Strategymentioning

confidence: 99%

Targeting ferroptosis for leukemia therapy: exploring novel strategies from its mechanisms and role in leukemia based on nanotechnology

Ashoub,

Razavi,

Heydaryan

et al. 2024

Eur J Med Res

View full text Add to dashboard Cite

The latest findings in iron metabolism and the newly uncovered process of ferroptosis have paved the way for new potential strategies in anti-leukemia treatments. In the current project, we reviewed and summarized the current role of nanomedicine in the treatment and diagnosis of leukemia through a comparison made between traditional approaches applied in the treatment and diagnosis of leukemia via the existing investigations about the ferroptosis molecular mechanisms involved in various anti-tumor treatments. The application of nanotechnology and other novel technologies may provide a new direction in ferroptosis-driven leukemia therapies. The article explores the potential of targeting ferroptosis, a new form of regulated cell death, as a new therapeutic strategy for leukemia. It discusses the mechanisms of ferroptosis and its role in leukemia and how nanotechnology can enhance the delivery and efficacy of ferroptosis-inducing agents. The article not only highlights the promise of ferroptosis-targeted therapies and nanotechnology in revolutionizing leukemia treatment, but also calls for further research to overcome challenges and fully realize the clinical potential of this innovative approach. Finally, it discusses the challenges and opportunities in clinical applications of ferroptosis.

show abstract